At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 744 enrolled
Drug / intervention
Tirasemtiv +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
In Brief
A Phase 3 clinical trial evaluating Tirasemtiv and Placebo tablets for Amyotrophic Lateral Sclerosis. Completed, enrolled 744 participants across 81 sites in 11 countries.
Detailed Summary
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesBelgium, Canada, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionMar 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJul 14, 2015
Enrollment StartSep 3, 2015
Primary CompletionMar 9, 2017
Study CompletionSep 27, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.0 years ago
Interventions
Tirasemtivdrug
Placebo tabletsdrug